Technology
Health
Biotechnology

Mersana Therapeutics

$4.92
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

$0.00 (0.00%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell MRSN and other stocks, options, ETFs, and crypto commission-free!

About

Mersana Therapeutics, Inc. engages in the development and manufacture of antibody drug conjugates to improve patient outcomes in multiple oncology indications. Its lead product candidates are XMT-1522, which focuses on breast cancer and non-small cell lung cancer (NSCLC); and XMT-1536, which targets ovarian cancer and NSCLC. Read More The company was founded by Mikhail Papisov in 2001 and is headquartered in Cambridge, MA.

Employees
86
Headquarters
Cambridge, Massachusetts
Founded
2001
Market Cap
114.31M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
162.04K
High Today
$4.97
Low Today
$4.82
Open Price
$4.88
Volume
45.79K
52 Week High
$23.96
52 Week Low
$2.85

Collections

Technology
Health
Biotechnology
Cancer Prevention
Therapy
2017 IPO
US
North America

News

BenzingaMar 11

JPMorgan Downgrades Mersana (NASDAQ:MRSN), Says Data Readouts Unlikely To Reverse Street Sentiment

Mersana Therapeutics Inc (NASDAQ: MRSN) shares, which went public in March 2018, was hit with its first bearish rating Monday in the absence of any stock-impacting data readouts over the next 12 months.

87
MarketWatchMar 11

Mersana Therapeutics Inc.

Biopharmaceutical company Mersana Therapeutics Inc. said Friday that it will discontinue development of its XMT-1522 cancer treatment, following a strategic evaluation by the company. The stock is currently halted for news. Instead, the company will focus its resources on advancing XMT-1536. XMT-1522 was being developed with its partner, Takeda Pharmaceutical Co. Ltd. . "We have made the difficult decision to terminate the further development of XMT-1522 despite a favorable emerging profile of efficacy and ...

48
Simply Wall StMar 8

Easy Come, Easy Go: How Mersana Therapeutics Shareholders Got Unlucky And Saw 72% Of Their Cash Evaporate

It’s not a secret that every investor will make bad investments, from time to time. But it would be foolish to simply accept every extremely large loss as an inevitable part of the game. So spare a thought for the long term shareholders of Mersana Therapeutics, Inc. (NASDAQ:MRSN); the share price is down a whopping 72% in the last twelve months. A loss like this is a stark reminder that portfolio diversification is important. Because Mersana Therapeutics hasn’t been listed for many years, the market is stil...

3

Earnings

-$6.33
-$4.34
-$2.34
-$0.35
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.69 per share
Actual
-$0.97 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.